IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
IDEXX Laboratories reported strong financial performance with 10% revenue growth, improved operating margins, and a significant increase in net income and EPS. The company also demonstrated strong free cash flow, indicating robust financial health. Despite the lack of strategic updates or risk discussion, the positive financial metrics are likely to lead to a positive stock price movement over the next two weeks.
Key Financial Performance
Revenue IDEXX Laboratories reported revenue of $1.2 billion for Q1 2026, representing a 10% increase year-over-year. This growth was driven by strong demand for diagnostic products and services, particularly in the Companion Animal Group (CAG) segment.
Operating Margin The operating margin for Q1 2026 was 25%, up from 23% in the prior year. The improvement was attributed to operational efficiencies and favorable product mix.
Net Income Net income for the quarter was $250 million, a 15% increase compared to Q1 2025. This was due to higher revenue and improved cost management.
Earnings Per Share (EPS) Earnings per share for Q1 2026 were $3.00, up from $2.60 in Q1 2025, reflecting a 15.4% increase. The rise was driven by higher net income and share repurchases.
Free Cash Flow Free cash flow for the quarter was $200 million, a 20% increase year-over-year. This was supported by strong earnings growth and disciplined capital expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Blair LLC
BofA Securities
CEO Director
Care Diagnostics
Citigroup Inc
Clark Leerink
Daniels Blair
Diagnostics Telemedicine
Director Erickson
Division Clark
Division EDT
Division Erin
Division Grosslight
Division Jonathan
Division Ryan
Division Schott
EDT measure
Emerson Executive
Erickson Executive
Executive VP
GM Point
Grosslight Citigroup
Inc Research
Jay Mazelsky
LLC Research
Point Care
Research Division
Telemedicine Ryskin
Treasurer Jay
VP GM
IDXX Transcript
IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
Positive5-5
IDEXX Laboratories reported strong financial performance with 10% revenue growth, improved operating margins, and a significant increase in net income and EPS. The company also demonstrated strong free cash flow, indicating robust financial health. Despite the lack of strategic updates or risk discussion, the positive financial metrics are likely to lead to a positive stock price movement over the next two weeks.
IDEXX Laboratories, Inc. (IDXX) Presents at 47th Annual Raymond James Institutional Investor Conference Prepared Remarks Transcript
Neutral3-2
IDEXX Laboratories, Inc. (IDXX) Q4 2025 Earnings Call Transcript
Positive2-2
The earnings call reflects strong financial performance with increased revenue and EPS guidance. Positive factors include significant growth in CAG Diagnostics, international expansion, and innovation in products like inVue and Cancer Dx. Despite some headwinds in wellness visits and pricing moderation, the overall outlook remains robust with improved margins and strategic expansion plans. The Q&A session confirms these positive trends, with management addressing concerns effectively, leading to a positive sentiment.
IDEXX Laboratories, Inc. (IDXX) Q3 2025 Earnings Call Transcript
Positive11-3
IDEXX's earnings call highlights strong financial performance with increased revenue and EPS outlooks, robust organic growth across multiple sectors, and strategic investments in commercial expansion and innovation. The Q&A session reinforces positive trends, particularly in consumables and diagnostics, despite minor declines in some areas like rapid assays. Share repurchases and a focus on long-term growth through R&D and market expansion further bolster confidence. The overall sentiment is positive, with expectations of continued growth and innovation driving stock price upward.
IDXX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
